



Route 206 and Province Line Road, Princeton, NJ 08543

February 21, 2025

Bristol-Myers Squibb Company Update on Abraxane CVR Payment for Fiscal Year 2024

As previously announced, on November 20, 2019, Bristol-Myers Squibb Company (the “Company”) acquired Celgene Corporation (“Celgene”) when it consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of January 2, 2019 (“Merger Agreement”), among the Company, Burgundy Merger Sub, Inc., a wholly owned subsidiary of the Company, and Celgene. In connection with the consummation of the transactions contemplated by the Merger Agreement, the Company assumed the contingent value rights related to Celgene’s Abraxane® and Abraxis pipeline products granted by Celgene to certain holders thereof pursuant to that certain Contingent Value Rights Agreement, dated as of October 15, 2010 (as amended, supplemented or otherwise modified from time to time, the “CVR Agreement”), between Equiniti Trust Company (the “Trustee”, as successor to American Stock Transfer & Trust Company, LLC) and the Company (as successor in interest to Celgene).

On February 21, 2025, the Company notified the Trustee that the Net Sales for Abraxane (as defined in the CVR Agreement) for the year ended December 31, 2024 is \$875,156,843 and that there is no Net Sales Payment (as defined in the CVR Agreement) due in respect of the year ended December 31, 2024, in accordance with Section 3.1 of the CVR Agreement. As previously noted, the Company reserves the right in accordance with the terms of the CVR Agreement, to disclose by means of its website at www.bms.com in the "Investors" section the Net Sales Payment due, if any, in respect of any subsequent Net Sales Measuring Period (as defined in the CVR Agreement).